Rovalpituzumab tesirine, also known as Rova-T, an antibody-drug conjugate being developed by AbbVie/Stemcentrx was recognized at the 7th Annual World Antibody Drug Conjugate (ADC) Awards as the “Most Promising Clinical Candidate” for fighting cancer.

Scott Dylla, AbbVie Stemcentrx vice president and chief scientific officer
Photo 1.0: Scott Dylla, AbbVie Stemcentrx vice president and chief scientific officer.

As an international conference, World ADC is considered the definitive forum for ADC thought leaders. The 7th Annual World ADC Summit, held in San Diego, CA, was attended by more than 650 colleagues and 90 ADC experts for 96 sessions on drug development, pre-clinical and clinical work and the latest intelligence in this area of oncology.

Early stage oncology asset
With the addition of rovalpituzumab tesirine and additional early stage and pre-clinical assets, AbbVie’s oncology portfolio consists of marketed medicines and a robust pipeline of new molecules being evaluated worldwide in nearly 200 clinical trials in 20 different tumor types.


AbbVie/Stemcentrx also won the top prize at World ADC for “Best Publication,” and AbbVie/Stemcentrx vice president and chief scientific officer Scott Dylla, Ph.D., was named runner-up for “Individual Input to the Field 2015/2016.”


Be a part of a community of ADC professionals and businesses. Share your expertise, discover new solutions, network with peers and grow your business. Become a member of the ADC Directory from the publishers of ADC Review. Join today!